Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in proliferative lupus nephritis or IgA nephropathy
NL-OMON60629Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and IgA nephropathy (IgAN) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Percentage change in proteinuria. Started Nov 2021; status: completed.
02
Drugs
ravulizumab
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON60629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60629.